Hanlon A - Search Results

1

Defining refractory migraine: results of the RHSIS Survey of American Headache Society members.

Schulman EA, Peterlin BL, Lake AE 3rd, Lipton RB, Hanlon A, Siegel S, Levin M, Goadsby PJ, Markley HG. Schulman EA, et al. Among authors: hanlon a. Headache. 2009 Apr;49(4):509-18. doi: 10.1111/j.1526-4610.2009.01370.x. Epub 2009 Feb 25. Headache. 2009. PMID: 19245385 Free article.

2

What dose of external-beam radiation is high enough for prostate cancer?

Eade TN, Hanlon AL, Horwitz EM, Buyyounouski MK, Hanks GE, Pollack A. Eade TN, et al. Among authors: hanlon al. Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):682-9. doi: 10.1016/j.ijrobp.2007.01.008. Epub 2007 Mar 29. Int J Radiat Oncol Biol Phys. 2007. PMID: 17398026 Free PMC article. Clinical Trial.

3

Comparison of evidence-based interventions on outcomes of hospitalized, cognitively impaired older adults.

Naylor MD, Hirschman KB, Hanlon AL, Bowles KH, Bradway C, McCauley KM, Pauly MV. Naylor MD, et al. J Comp Eff Res. 2014 May;3(3):245-57. doi: 10.2217/cer.14.14. J Comp Eff Res. 2014. PMID: 24969152 Free PMC article. Clinical Trial.

4

Radiation therapy dose escalation for prostate cancer: a rationale for IMRT.

Pollack A, Hanlon A, Horwitz EM, Feigenberg S, Uzzo RG, Price RA. Pollack A, et al. Among authors: hanlon a. World J Urol. 2003 Sep;21(4):200-8. doi: 10.1007/s00345-003-0356-x. Epub 2003 Sep 5. World J Urol. 2003. PMID: 12961097 Review.

5

MRI simulation: effect of gradient distortions on three-dimensional prostate cancer plans.

Mah D, Steckner M, Hanlon A, Freedman G, Milestone B, Mitra R, Shukla H, Movsas B, Horwitz E, Väisänen PP, Hanks GE. Mah D, et al. Among authors: hanlon a. Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):757-65. doi: 10.1016/s0360-3016(02)02782-7. Int J Radiat Oncol Biol Phys. 2002. PMID: 12062622

6

Measurement of intrafractional prostate motion using magnetic resonance imaging.

Mah D, Freedman G, Milestone B, Hanlon A, Palacio E, Richardson T, Movsas B, Mitra R, Horwitz E, Hanks GE. Mah D, et al. Among authors: hanlon a. Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):568-75. doi: 10.1016/s0360-3016(02)03008-0. Int J Radiat Oncol Biol Phys. 2002. PMID: 12243837

7

Predictors of preferences and utilities in men treated with 3D-CRT for prostate cancer.

Bruner DW, Hanlon A, Mazzoni S, Raysor S, Konski A, Hanks G, Pollack A. Bruner DW, et al. Among authors: hanlon a. Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):34-42. doi: 10.1016/s0360-3016(03)01434-2. Int J Radiat Oncol Biol Phys. 2004. PMID: 14697418

8

Does age matter in the selection of treatment for men with early-stage prostate cancer?

Konski A, Eisenberg D, Horwitz E, Hanlon A, Pollack A, Hanks G. Konski A, et al. Among authors: hanlon a. Cancer. 2006 Jun 15;106(12):2598-602. doi: 10.1002/cncr.21923. Cancer. 2006. PMID: 16683224 Free article.

9

Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer.

Konski A, Watkins-Bruner D, Feigenberg S, Hanlon A, Kulkarni S, Beck JR, Horwitz EM, Pollack A. Konski A, et al. Among authors: hanlon a. Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):408-15. doi: 10.1016/j.ijrobp.2006.04.049. Epub 2006 Aug 2. Int J Radiat Oncol Biol Phys. 2006. PMID: 16887291

10

Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death.

Alcantara P, Hanlon A, Buyyounouski MK, Horwitz EM, Pollack A. Alcantara P, et al. Among authors: hanlon a. Cancer. 2007 Jan 1;109(1):41-7. doi: 10.1002/cncr.22341. Cancer. 2007. PMID: 17133416 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

538 results

Search Page